Head to Head Review: DARA Biosciences (DARA) vs. Its Competitors
DARA Biosciences (NASDAQ: DARA) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare DARA Biosciences to similar companies based on the strength of its dividends, risk, earnings, valuation, profitability, analyst recommendations and institutional ownership.
This table compares DARA Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DARA Biosciences Competitors||-547.73%||-39.45%||-21.59%|
This is a breakdown of recent ratings for DARA Biosciences and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DARA Biosciences Competitors||72||343||997||29||2.68|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.52%. Given DARA Biosciences’ competitors higher possible upside, analysts plainly believe DARA Biosciences has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares DARA Biosciences and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DARA Biosciences Competitors||$3.02 billion||$642.98 million||-87.33|
DARA Biosciences’ competitors have higher revenue and earnings than DARA Biosciences. DARA Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
DARA Biosciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, DARA Biosciences’ competitors have a beta of 0.96, suggesting that their average stock price is 4% less volatile than the S&P 500.
Insider and Institutional Ownership
65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
DARA Biosciences competitors beat DARA Biosciences on 7 of the 8 factors compared.
About DARA Biosciences
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
Receive News & Ratings for DARA Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.